Novo Nordisk A/S (NVO)
After hours:
| Previous Close | 108.43 |
| Open | 111.81 |
| Bid | 106.41 x 800 |
| Ask | 112.25 x 800 |
| Day's Range | 110.58 - 112.20 |
| 52 Week Range | 82.82 - 122.16 |
| Volume | |
| Avg. Volume | 1,476,990 |
| Market Cap | 255.587B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 36.93 |
| EPS (TTM) | 3.04 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.57 (1.48%) |
| Ex-Dividend Date | Mar 25, 2022 |
| 1y Target Est | 130.93 |
- CNW Group
Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Insul-Inn
Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment.
- GlobeNewswire
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 20 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat
- Zacks
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
